Bespak and H&T Presspart collaborate to advance transition to low-GWP propellants in pMDIs

Published: 7-May-2024

Partnership will provide GMP filling capabilities and development support for clinical trial programmes with low GWP propellants

Bespak, a CDMO focused on orally inhaled and nasal drug-device combination products and H&T Presspart, a specialist in the development, manufacturing and supply of inhaled drug delivery components and devices, is collaborating to accelerate the industry’s transition from existing pressurised Metered Dose Inhaler (pMDI) formulations to more climate-friendly alternatives utilising low global warming potential (GWP) propellants. 

The partnership will bring rapid access to small-scale filling capabilities in GMP conditions to support development programs and clinical trials with both HFA-152a and HFO-1234ze propellants.

The collaboration leverages H&T Presspart’s expertise in inhalation product development, the company’s low GWP filling equipment and market-leading portfolio of componentry, as well as Bespak’s expertise and in valves, formulation development and finished product manufacturing.

The partnership will accelerate industry understanding and customer success in the reformulation and commercialisation of products with a significantly lower environmental footprint. 

Chris Hirst, CEO of Bespak, commented: “Making the transition to more sustainable, low GWP propellants in pMDIs is highly important for the industry, and in collaboration with H&T Presspart, we are able to offer a unique combination of capabilities and expertise to support our customers to transition as efficiently as possible."


You may also like